Abstract:Objective:To study of the effect and mechanism of modified Erchentang on Clara cell protein (CC16),pulmonary surfactant associated protein-D (SP-D),histone acetyl transferase (HAT) and histone deacetylase (HDAC) in patients at acute aggravating stage of COPD.Method:Totally 200 cases at acute exacerbation period of COPD (AECOPD) were randomly divided into modified Erchentang group and placebo-controlled group,with 100 cases in each group.In addition to western drugs,modified Erchentang was also used in the modified Erchentang group,and placebo was also used in control group for 14 days.Their pulmonary function was detected,and euzyme-linked immunosorbent assay was used to determine the levels of C-reactive protein (CRP),interleukin-17 (IL-17),CC16,SP-D,HDAC1 and HAD2 in plasma and exhaled breath condensate of all groups.The activities of HAT and HDAC were determinate by enzyme-linked immune fluorescence.Result:The activity of HDAC2 was higher significantly,but the levels of CRP,IL-17,CC16 and SP-D (P ＜0.05,P ＜0.01) in plasma and exhaled breath condensate,and the activity of HAT were significantly decreased in treatment group with modified Erchentang,compared with those in control group.Conclusion:Modified Erchentang may have an effect on COPD by adjusting the HAT/HDAC,reducing levels of CRP,IL-17,CC16 and SP-D,preventing inflammation progress and improving the structure and function of respiratory system and lungs.

Effect of Modified Erchentang on CC16, SP-D and HAT and HDAC in Patients at Acute Exacerbation Stage of COPD